多発性骨髄腫治療薬の世界市場予測および分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 27
3.2 Staging Systems 30
3.3 Response and Relapse Criteria 31
3.4 Symptoms 33
3.5 Prognosis 34
3.6 Quality of Life 35
4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and Comorbidities 39
4.3 Global Trends 40
4.3.1 Incidence 40
4.3.2 Survival Rates for Multiple Myeloma – 8MM 43
4.4 Forecast Methodology 44
4.4.1 Sources Used 46
4.4.2 Sources Not Used 48
4.4.3 Forecast Assumptions and Methods, Multiple Myeloma Diagnosed Incident Cases 48
4.4.4 Forecast Assumptions and Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases 49
4.4.5 Forecast Assumptions and Methods, Multiple Myeloma Clinical Stages at Diagnosis 50
4.5 Epidemiological Forecast for Multiple Myeloma (2013-2023) 50
4.5.1 Diagnosed Incident Cases of Multiple Myeloma 50
4.5.2 Age-Specific Diagnosed Incident Cases of Multiple Myeloma 52
4.5.3 Sex-Specific Diagnosed Incident Cases of Multiple Myeloma 54
4.5.4 Age-Standardized Diagnosed Incidence of Multiple Myeloma 56
4.5.5 Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis 57
4.5.6 Five-Year Diagnosed Prevalent Cases of Multiple Myeloma 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 60
4.6.3 Strengths of the Analysis 61
5 Disease Management 62
5.1 Treatment Overview 62
5.2 Diagnosis 63
5.3 Clinical Practice 64
5.3.1 Primary Therapy for SCT-Eligible Patients 65
5.3.2 Primary Therapy for Non-SCT Patients 67
5.3.3 Salvage/Relapse Therapy 68
5.3.4 Leading Prescribed Drugs 69
5.4 US 71
5.4.1 Diagnosis 72
5.4.2 Clinical Practice 73
5.5 France 75
5.5.1 Diagnosis 76
5.5.2 Clinical Practice 77
5.6 Germany 77
5.6.1 Diagnosis 79
5.6.2 Clinical Practice 79
5.7 Italy 79
5.7.1 Diagnosis 81
5.7.2 Clinical Practice 81
5.8 Spain 83
5.8.1 Diagnosis 84
5.8.2 Clinical Practice 84
5.9 UK 85
5.9.1 Diagnosis 86
5.9.2 Clinical Practice 87
5.10 Japan 87
5.10.1 Diagnosis 88
5.10.2 Clinical Practice 89
5.11 China (Urban) 90
5.11.1 Diagnosis 91
5.11.2 Clinical Practice 92
6 Competitive Assessment 93
6.1 Overview 93
6.2 Product Profiles – Proteasome Inhibitors 93
6.2.1 Velcade (Bortezomib) 93
6.2.2 Kyprolis (Carfilzomib) 100
6.3 Product Profiles – Immunomodulators 108
6.3.1 Revlimid (Lenalidomide) 108
6.3.2 Pomalyst/Imnovid (Pomalidomide) 115
6.4 Other Therapeutic Classes 120
7 Unmet Need and Opportunity 121
7.1 Overview 121
7.2 Treatment of High-Risk Patients 121
7.2.1 Unmet Need 121
7.2.2 Gap Analysis 122
7.2.3 Opportunity 123
7.3 Treatment of Patients with Smoldering Myeloma 123
7.3.1 Unmet Need 123
7.3.2 Gap Analysis 125
7.3.3 Opportunity 125
7.4 Treatment of Extramedullary Disease 126
7.4.1 Unmet Need 126
7.4.2 Gap Analysis 126
7.4.3 Opportunity 127
8 Pipeline Assessment 128
8.1 Overview 128
8.2 Promising Drugs in Clinical Development 128
8.2.1 Farydak (Panobinostat) 128
8.2.2 Ixazomib 135
8.2.3 Empliciti (Elotuzumab) 140
8.2.4 Daratumumab 146
8.2.5 Aplidin (Plitidepsin) 151
8.3 Promising Drugs in Early-Stage Development 155
8.3.1 Oprozomib (ONX-0912) 155
8.3.2 Filanesib 156
8.3.3 SAR650984 156
8.3.4 Marizomib 158
8.3.5 Evofosfamide 158
8.3.6 LGH447 159
8.3.7 Selinexor (KPT-330) 159
9 Current and Future Players 161
9.1 Overview and Trends in Corporate Strategy 161
9.2 Company Profiles 164
9.2.1 Millennium Pharmaceuticals/Takeda 164
9.2.2 Celgene 166
9.2.3 Onyx Pharmaceuticals/Amgen 168
9.2.4 Novartis 169
9.2.5 AbbVie 171
9.2.6 Bristol-Myers Squibb 172
9.2.7 Janssen 173
10 Market Outlook 175
10.1 Global Markets 175
10.1.1 Forecast 175
10.1.2 Drivers – Global Issues 182
10.1.3 Barriers – Global Issues 183
10.2 US 184
10.2.1 Forecast 184
10.2.2 Key Events 188
10.2.3 Drivers – US 188
10.2.4 Barriers – US 190
10.3 5EU 191
10.3.1 Forecast 191
10.3.2 Key Events 196
10.3.3 Drivers – 5EU 196
10.3.4 Barriers – 5EU 198
10.4 Japan 200
10.4.1 Forecast 200
10.4.2 Key Events 203
10.4.3 Drivers – Japan 203
10.4.4 Barriers – Japan 204
10.5 China (Urban) 205
10.5.1 Forecast 205
10.5.2 Key Events 208
10.5.3 Drivers – China (Urban) 208
10.5.4 Barriers – China (Urban) 209
11 Appendix 211
11.1 Bibliography 211
11.2 Abbreviations 233
11.3 Methodology 237
11.4 Forecasting Methodology 237
11.4.1 Diagnosed Multiple Myeloma Patients 237
11.4.2 Percent of Drug-Treated Patients 238
11.4.3 Drugs Included in Each Therapeutic Class 238
11.4.4 Launch and Patent Expiry Dates 239
11.4.5 General Pricing Assumptions 240
11.4.6 Individual Drug Assumptions 241
11.4.7 Pricing of Pipeline Agents 248
11.4.8 Generic Erosion 255
11.5 Primary Research – KOLs Interviewed for this Report 256
11.6 Primary Research – High-Prescriber Survey 258
11.7 About the Authors 259
11.7.1 Analyst 259
11.7.2 Therapy Director 259
11.7.3 Epidemiologist 259
11.7.4 Global Head of Healthcare 260
11.8 About GlobalData 261
11.9 Disclaimer 261